Patents by Inventor Tatsuo Suda

Tatsuo Suda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody recognizing human 25-hydroxyvitamin D3-1a-hydroxylase
    Publication number: 20020031798
    Abstract: The present invention relates to a polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D3 and catalyzing the final stage of vitamin D3 activation; and the gene encoding the polypeptide.
    Type: Application
    Filed: June 12, 2001
    Publication date: March 14, 2002
    Inventors: Hideharu Anazawa, Hiroko Shimada, Seiji Sugimoto, Tatsuo Suda, Toshimasa Shinki, Takao Saruta, Yuzuru Ishimura, Matsuhiko Hayashi, Shu Wakino, Toshiaki Monkawa, Tadashi Yoshida, Hiromichi Suzuki
  • 25-hydroxyvitamin D3-1&agr;-hydroxylase and DNA encoding the hydroxylase
    Patent number: 6274359
    Abstract: The present invention relates to a polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D3 and catalyzing the final stage of vitamin D3 activation; and the gene encoding the polypeptide. In accordance with the present invention, the following can be provided; a polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, DNA encoding the polypeptide, a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for preparing 25-hydroxyvitamin D3-1&agr;-hydroxylase by using the transformant, a method for preparing 1&agr;, 25-dihydroxyvitamin D3 comprising using the polypeptide having 25-hydroxyvitamin D3-1&agr;-hydroxylase activity, and an antibody recognizing the polypeptide.
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: August 14, 2001
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Hideharu Anazawa, Hiroko Shimada, Seiji Sugimoto, Tatsuo Suda, Toshimasa Shinki, Takao Saruta, Yuzuru Ishimura, Matsuhiko Hayashi, Shu Wakino, Toshiaki Monkawa, Tadashi Yoshida, Hiromichi Suzuki
  • Peptide or its salts
    Patent number: 5624900
    Abstract: Peptides having high binding activity for human interleukin-1 and represented by the following formulaH-X.sup.1 -Cys-A-B-A-B-A-Ser-X.sup.2 -Ywherein each A represents an amino acid residue selected from the group consisting of Val, Leu, Ile and Nle, independent of any other selection for A; B represents an amino acid residue selected from the group consisting of Arg, Lys, Gln, His and Ser, independent of any other selection for B; X.sup.1 and X.sup.2 each is a single bond or a peptide segment comprising 1-10 amino acid residues selected from Gly, Ala, Val, Arg, Asn, Ser, Phe, Pro, Leu, Glu, Asp, Lys, Thr, His, Tyr, Nle and Ile and Y represents a hydroxyl group or an amino group; and their salts.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: April 29, 1997
    Assignee: Kuraray Co., Ltd.
    Inventors: Tatsuo Suda, Etsuko Abe, Masao Tanihara, Chie Fujiwara
  • Novel vitamin D.sub.3 derivatives and process for producing the same
    Patent number: 4517125
    Abstract: There are disclosed 6,19-epidioxyvitamin D.sub.3 derivatives which are represented by the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each a hydrogen atom or a hydroxyl group; when R.sub.1 is a hydrogen atom, R.sub.2 represents a hydroxyl group and R.sub.3 is a hydrogen atom or a hydroxyl group; when both R.sub.1 and R.sub.2 represent a hydroxyl group, R.sub.3 is a hydrogen atom or a hydroxyl group; and when R.sub.1 is a hydroxyl group and R.sub.2 is a hydrogen atom, R.sub.3 represents a hydroxyl group. The compounds are highly capable of inducing differentiation of human myeloid leukemia cells with minimum effects on calcium metabolism and are useful as an agent to treat leukemia.
    Type: Grant
    Filed: February 3, 1983
    Date of Patent: May 14, 1985
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroaki Takayama, Sachiko Yamada, Keiko Nakayama, Tatsuo Suda
  • Method of treating leukemia or leukemoid diseases
    Patent number: 4391802
    Abstract: A method of leukemia or leukemoid disease treatment by administration of a vitamin D derivative with a hydroxyl group at 1.alpha.-position is disclosed. It is believed that the vitamin D derivative with a hydroxyl group at 1.alpha.-position is capable of treating cancer through redifferentiation of cancer cells and that this capability is inherent in vitamin D derivatives with a hydroxyl group at 1.alpha.-position.
    Type: Grant
    Filed: March 9, 1982
    Date of Patent: July 5, 1983
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tatsuo Suda, Yoshihei Hirasawa, Sachio Takahashi, Etsuko Abe, Kunio Konno, Tadao Aoki
  • 1.alpha., 2.alpha.-Dihydroxycholecalciferol and process for preparing the same
    Patent number: 4011250
    Abstract: 1.alpha.,2.alpha.-Dihydroxycholecaliciferol having improved vitamin D activities and a process for preparing the same are disclosed.
    Type: Grant
    Filed: August 6, 1975
    Date of Patent: March 8, 1977
    Assignees: Masayuki Ishikawa, Chikara Kaneko, Satoshi Sasaki, Tatsuo Suda
    Inventors: Masayuki Ishikawa, Chikara Kaneko, Satoshi Sasaki, Tatsuo Suda, Sachiko Yamada, Akiko Sugimoto